Abstract 198P
Background
Women with breast cancer with impaired immunity develop life-threatening clinical disease. Findings of tumor-associated lymphocytes in tumor specimens are explicit evidence of immunologic sensitivity to this. Despite several treatment modalities, the majority of patients eventually relapse. However, immunotherapy – a new promising modality for treatment - has been advocated to command disease progress. Cancer immunoediting provided insights that the immune system has both immune surveillance and tumor promotion effects during cancer development. Anti-tumor immune response requires involvement of both CD4+ and CD8+ T cells. Thus, for better understanding the roles of CD4+ CD8 and regulatory T cells in pathogenesis and progression of breast cancer, the following study was designed to be conducted in clinical patients with breast cancer. 1-To determine expression of FOXP3 CD25, CD4, CD8 before therapy in blood, and tumor tissue. 2-Impact of surgery and chemotherapy on immunological status of tumour in breast cancer patients.
Methods
This was a prospective observational pilot study. Patients: N=30, locally advanced and metastatic breast cancer patients receiving chemotherapy as first modality of treatment (NACT group). N=30, early breast cancer patients receiving surgery as first modality of treatment (Upfront surgery). Control: N=30, Sex matched group undergoing surgery for benign breast disease.
Results
In the pre-treatment group lower expression of CD4 and higher CD8 and Tregs were found as the disease progresses. After upfront surgery CD4 counts increase with decrease of CD8 and Tregs cells. There was no change in CD4 in the control after surgery with positive correlation in CD8 and Tregs. Higher CD4 counts with lower CD8 and Tregs were found in patients after NACT.
Conclusions
T-cell subgroups in breast cancer patients undergo dynamic, significant changes during surgery and chemotherapy. Comprehensive analysis of characteristic T cell repertoire in breast cancer has depicted a landscape of possibilities of developing a blood-based therapeutic or preventive (vaccine) modality to enhance the armamentarium against this cancer.
Legal entity responsible for the study
AIIMS.
Funding
AIIMS New Delhi.
Disclosure
The author declared no conflicts of interest.
Resources from the same session
216P - Spatial transcriptomics reveals tumor-microenvironment heterogeneity of breast cancer
Presenter: Hyun Lee
Session: Poster Display session
Resources:
Abstract
217P - Tumor-derived CCL15 regulates RNA m6A methylation in cancer-associated fibroblasts to promote hepatocellular carcinoma growth
Presenter: Yueguo Li
Session: Poster Display session
Resources:
Abstract
218P - A novel tumor adenosine signature to guide indication selection for adenosine pathway inhibitors
Presenter: Sophie Dekoninck
Session: Poster Display session
Resources:
Abstract
219P - Radiotherapy, in conjunction with a PI3Kd/? inhibitor, enhances effector CD8+ T cell-mediated anti-tumor immune responses and the memory function of T cells within the tumor microenvironment by stimulating innate immunity
Presenter: Ye hyun Kim
Session: Poster Display session
Resources:
Abstract
220P - Correlation research between oral flora diversity and radiation-induced stomatitis after postoperative radiotherapy for oral squamous cell carcinoma
Presenter: Qin Zheng
Session: Poster Display session
Resources:
Abstract
221P - Chemoradiotherapy induced adaptive anti-tumor T cell immunity in patients with non-small cell lung cancer
Presenter: Yaoyao Xie
Session: Poster Display session
Resources:
Abstract
222P - Features of epithelial-to-mesenchymal transition (EMT) and humoral immune response in ulcerated acral melanoma: A transcriptomic and spatial proteomic analysis.
Presenter: Estefania Vazquez
Session: Poster Display session
Resources:
Abstract
223P - Frequency of the number of myeloid-derived suppressor cells in patients with lung cancer according to T stage
Presenter: Jelena Vukovic
Session: Poster Display session
Resources:
Abstract
224P - Immunological Dynamics in Triple-Negative Breast Cancer: Peripheral Immune Responses to Neoadjuvant Therapy
Presenter: Rita Santos
Session: Poster Display session
Resources:
Abstract
225P - Assessment of immune cell populations in the peripheral blood of metastatic prostate cancer
Presenter: Vanessa Patel
Session: Poster Display session
Resources:
Abstract